Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT03729453
Active, not recruiting Observational

Intra-operative Pancreatoscopy in Patients With IPMN

NCT03729453 · tracked via the Priya Life Science China tracker
Sponsor
Boston Scientific Corporation
Phase
Observational
Started
2019-03-20
Last updated
2026-07-24

Condition(s) studied

Intraductal Papillary Mucinous Neoplasm

Investigational drug(s) / intervention(s)

SpyGlass

SpyGlass: Visualization of main pancreatic duct with SpyGlass catheter.

Study summary

To demonstrate the added value of intraoperative pancreatoscopy in patients undergoing partial pancreatic resection for the treatment of Intraductal Papillary Mucinous Neoplasm (IPMN) as it pertains to detection of discontinuous (skip) lesions in the remnant pancreas; to generate a hypothesis for a subsequent randomized control trial.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patient scheduled for surgery for suspected MD-IPMN or Mixed IPMN within 4-6 weeks of enrollment 2. Diameter of pancreatic main duct \>5mm on pre-operative MRI or CT 3. Written informed consent from patient to participate in the study, including compliance with study procedures Exclusion Criteria: 1. Contraindication for pancreatoscopy 2. Age: less than 18 years 3. Pregnant women, evaluated per local clinical standard

Primary outcome measure(s)

  • Rate of detection of discontinuous (skip) lesions along the main pancreatic duct — During index procedure
    Rate of detection of discontinuous (skip) lesions along the main pancreatic duct of patients with IPMN using intraoperative pancreatoscopy based on visual impression of IPMN and/or pancreatoscopy guided biopsies

Trial sites (8)

FacilityCityRegionStatus
University of Colorado Hospital Denver Colorado
Indiana University Health Indianapolis Indiana
Johns Hopkins Hospital University Baltimore Maryland
The First Affiliated Hospital of Nanjing Medical University Nanjing China
Asian Institute of Gastroenterology Hyderabad India
Kansai Medical University Hirakata Osaka
Academic Medical Center Amsterdam Netherlands
University Hospital of UMEA Umeå Sweden

More Boston Scientific Corporation trials in China

IT Matters: The Erectile Restoration Registry Enrolling by invitation
FARAPULSE™ Pulsed Field Ablation System Active, not recruiting
PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II) Recruiting
A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China Active, not recruiting
Combined CM and STN Stimulation for Motor Epilepsy Recruiting

Other trials for the same condition

Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas Recruiting
AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort Recruiting
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer Recruiting
Intent of Surgery for IPMN Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03729453 on ClinicalTrials.gov ↗ ← All trials in China